Last November, Novartis secured European approval for a gene therapy against a rare form of blindness. Six months later, not a single patient has been treated, illustrating the challenges that drug makers face when trying to sell high-priced, one-time medicines in Europe.

Now, Bluebird Bio (BLUE) is nearing European approval of its first gene therapy for a rare blood disorder. An announcement could come within weeks. On Thursday, the biotech offered new details about its commercial plans, telling investors and analysts at a meeting in New York that it hopes to move faster than Novartis while cautioning against expectations for a flying start.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy